MID-VOLUME · SEX-BALANCED
benralizumab Side Effects
benralizumab (also sold as Fasenra) sits MID-VOLUME #251 of 524 by FAERS report count. Lead signal: SEX-BALANCED - 70% of sex-coded reports are female (11,037 F / 4,811 M). Demographics and serious-outcome tables follow.
Data updated 2026-05-15
- 17,680
- FAERS reports
FDA Adverse Event Reporting System extract for benralizumab. Stamp set WATCHLIST · DEATH-HEAVY · HOSP-MID. How figures are compiled.
benralizumab reporting skew - 70% of sex-coded reports are female (11,037 F / 4,811 M). Volume band MID-VOLUME #251 of 524 by FAERS report count; caseload WATCHLIST.
Mid-book FAERS page for benralizumab (Fasenra) (17,680 reports). Signature SEX-BALANCED. Dominant age band on file: 45-64. Educational reference only.
Counts from the openFDA FAERS extract (2012–2025). Stamps WATCHLIST · DEATH-HEAVY · HOSP-MID · SEX-BALANCED.
ASTHMA leads 2,775 of 17,680 reports
Who reports · age peak 45-64 (SEX-BALANCED)
Sex coding · SEX-BALANCED
Age peak 45-64 (1,909 reports)
FAERS filings rising toward 2025
Reactions in Death Reports
Death-mentioned subset is HEAVY here (1,749 reports, 9.9%). Top co-reported reactions in that subset - voluntary, not causal.
| Reaction | Reports |
|---|---|
| DEATH | 1,434 |
| PNEUMONIA | 45 |
| ASTHMA | 42 |
| COVID-19 | 26 |
| RESPIRATORY FAILURE | 22 |
| DYSPNOEA | 20 |
| CARDIAC ARREST | 19 |
| MYOCARDIAL INFARCTION | 16 |
| FALL | 13 |
| ABORTION SPONTANEOUS | 12 |
| CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 12 |
| EPILEPSY | 12 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 12 |
| INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION | 11 |
| LUNG DISORDER | 11 |
| CARDIAC FAILURE | 10 |
| MALAISE | 9 |
Reactions in Hospitalization Reports
Hospitalization mid-share (4,130, 23.4%). Co-reported reactions:
| Reaction | Reports |
|---|---|
| ASTHMA | 1,048 |
| DYSPNOEA | 536 |
| PNEUMONIA | 464 |
| COUGH | 217 |
| WHEEZING | 180 |
| COVID-19 | 175 |
| PYREXIA | 172 |
| INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION | 171 |
| MALAISE | 170 |
| FALL | 157 |
| HEADACHE | 145 |
| FATIGUE | 126 |
| ILLNESS | 123 |
| INFLUENZA | 116 |
| ASTHENIA | 103 |
| PAIN | 103 |
| CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 102 |
| INFECTION | 98 |
How to read benralizumab FAERS figures (WATCHLIST · DEATH-HEAVY · HOSP-MID)
FAERS holds 17,680 voluntary reports linked to benralizumab (Fasenra), 2012-2025. Death is listed on 1,749 (9.9%). Hospitalization appears on 4,130 (23.4%). Top co-reported indication: Asthma.
Mid-volume extract - treat DEATH-HEAVY · HOSP-MID as signal-detection rates next to 70% of sex-coded reports are female (11,037 F / 4,811 M).
Read with benralizumab
Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-HEAVY · HOSP-MID stamps.
ABS(total_reports) peer at 17,740 FAERS cases (Δ 60 heavier vs benralizumab); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-MID · SEX-BALANCED.
ABS(total_reports) peer at 17,512 FAERS cases (Δ 168 lighter vs benralizumab); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-MID · SEX-BALANCED.
ABS(total_reports) peer at 17,969 FAERS cases (Δ 289 heavier vs benralizumab); DEATH-HEAVY · HOSP-HEAVY · FEMALE-LED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-MID · SEX-BALANCED.
ABS(total_reports) peer at 17,976 FAERS cases (Δ 296 heavier vs benralizumab); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-MID · SEX-BALANCED.
ABS(death_share) pole at 62.1% death-mentioned reports (Δ 52.2 pp vs benralizumab's DEATH-HEAVY): CASELOAD · HOSP-MID.
benralizumab stamps DEATH-HEAVY · HOSP-MID; FAERS outcome shares are signal-detection rates, not incidence. Read them next to caseload WATCHLIST and the label guide.